The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

A scientific statement regarding sex differences in patients with peripheral vascular disease has been published by the AHA.

COLUMBIA SC (WOLO) – We all understand the importance of the heart, but there are some other afflictions related to the ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...